U.S. Markets open in 2 hrs 24 mins

Six months after IPO filing, Peninsula biotech's offering is on again — and upsized

Ron Leuty
Six months after IPO filing, Peninsula biotech's offering is on again — and upsized

Lots has changed for the South San Francisco company since it first filed its IPO plans in September: It now has a clear game plan for its drug portfolio — stretching from type 2 diabetes and the fatty liver disease NASH to cancer and a vision-blurring eye disease — and a renewed collaboration with drug giant Merck.